Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2018 | 1 |
2022 | 3 |
2024 | 0 |
Search Results
4 results
Results by year
Filters applied: . Clear all
Page 1
Macrophage-NLRP3 Activation Promotes Right Ventricle Failure in Pulmonary Arterial Hypertension.
Am J Respir Crit Care Med. 2022 Sep 1;206(5):608-624. doi: 10.1164/rccm.202110-2274OC.
Am J Respir Crit Care Med. 2022.
PMID: 35699679
Free PMC article.
Methods: Rats with decompensated RV hypertrophy (monocrotaline [MCT] and Sugen-5416 hypoxia [SuHx]) were compared with compensated RV hypertrophy rats (pulmonary artery banding). ...
Methods: Rats with decompensated RV hypertrophy (monocrotaline [MCT] and Sugen-5416 hypoxia [SuHx]) were compared with compensated RV …
Loss of lung microvascular endothelial Piezo2 expression impairs NO synthesis, induces EndMT, and is associated with pulmonary hypertension.
Tian S, Cai Z, Sen P, van Uden D, van de Kamp E, Thuillet R, Tu L, Guignabert C, Boomars K, Van der Heiden K, Brandt MM, Merkus D.
Tian S, et al.
Am J Physiol Heart Circ Physiol. 2022 Nov 1;323(5):H958-H974. doi: 10.1152/ajpheart.00220.2022. Epub 2022 Sep 23.
Am J Physiol Heart Circ Physiol. 2022.
PMID: 36149769
Free article.
The expression of Piezo2 was significantly reduced in pulmonary microvascular endothelial cells (MVECs) from patients with PAH, in lung tissue from mice with a Bmpr2(+/R899X) knock-in mutation commonly found in patients with pulmonary hypertension, and in lung tissue of monocrota …
The expression of Piezo2 was significantly reduced in pulmonary microvascular endothelial cells (MVECs) from patients with PAH, in lung tiss …
Item in Clipboard
Kynurenine metabolites predict survival in pulmonary arterial hypertension: A role for IL-6/IL-6Rα.
Cai Z, Tian S, Klein T, Tu L, Geenen LW, Koudstaal T, van den Bosch AE, de Rijke YB, Reiss IKM, Boersma E, van der Ley C, Van Faassen M, Kema I, Duncker DJ, Boomars KA, Tran-Lundmark K, Guignabert C, Merkus D.
Cai Z, et al.
Sci Rep. 2022 Jul 19;12(1):12326. doi: 10.1038/s41598-022-15039-3.
Sci Rep. 2022.
PMID: 35853948
Free PMC article.
KP-metabolite levels were determined in plasma from PAH patients (median follow-up 42 months) and in rats with monocrotaline- and Sugen/hypoxia-induced PH. Blood sampling of PAH patients was performed at the time of diagnosis, six months and one year after PAH therapy. ... …
KP-metabolite levels were determined in plasma from PAH patients (median follow-up 42 months) and in rats with monocrotaline- and Sugen …
Item in Clipboard
ASK1 Inhibition Halts Disease Progression in Preclinical Models of Pulmonary Arterial Hypertension.
Budas GR, Boehm M, Kojonazarov B, Viswanathan G, Tian X, Veeroju S, Novoyatleva T, Grimminger F, Hinojosa-Kirschenbaum F, Ghofrani HA, Weissmann N, Seeger W, Liles JT, Schermuly RT.
Budas GR, et al.
Am J Respir Crit Care Med. 2018 Feb 1;197(3):373-385. doi: 10.1164/rccm.201703-0502OC.
Am J Respir Crit Care Med. 2018.
PMID: 28910144
METHODS: A selective, orally available ASK1 inhibitor, GS-444217, was administered to two preclinical rat models of PAH (monocrotaline and Sugen/hypoxia), a murine model of RV pressure overload induced by pulmonary artery banding, and cellular models. ...
METHODS: A selective, orally available ASK1 inhibitor, GS-444217, was administered to two preclinical rat models of PAH (monocrotaline and …
Item in Clipboard
Cite
Cite